CyanVac

CyanVac develops vaccines using a proprietary transformative parainfluenza virus type 5 (PIV5) vector. It is currently focused on developing robust intranasal vaccines that are easy to administer, transport, and manufacture, with the mission of addressing the world's most pressing infectious diseases through vaccines that can be easily delivered worldwide.